Incyte Deal History & Licensing Activity
Incyte is a biotech headquartered in US. Over the past three years, Incyte has been involved in 7 licensing and acquisition transactions, with a primary focus on Small Molecules (5 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
3
Active Trials
50
Top Modality
Small Molecules
Focus Area
Solid Tumors
Incyte Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Incyte in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| VGA039 (Protein S modulator) | Vega Therapeutics | Other | Phase 3 | acquisition | Jun 8, 2026 |
| zilurgisertib | Mirum Pharmaceuticals | Small Molecules | Phase 3 | license | Apr 1, 2026 |
| PRT12396 (JAK2V617F program) | Prelude Therapeutics | Small Molecules | Preclinical | option | Nov 4, 2025 |
Incyte Pipeline Focus
Therapeutic areas and modalities where Incyte is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Incyte Strategic Signals
Key indicators of Incyte's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Incyte Clinical Pipeline
Incyte has 50 active clinical trials across 4 development phases.
1
Unknown
22
Phase 1
14
Phase 2
13
Phase 3
See How Your Asset Matches Incyte's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Hematology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for hematology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Incyte Licensing & Deal Activity
Incyte is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 7 deals over the past three years, Incyte ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Incyte include Solid Tumors (16 deals and trials), Hematological Malignancies (12 deals and trials), Hematology (5 deals and trials), and Autoimmune (5 deals and trials). In terms of modality, Incyte has shown particular interest in small molecules, other, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Incyte and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Incyte's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.